Form 4: Halozyme Therapeutics SVP, Chief Legal Officer Reports Stock Transactions

Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.

Summary

• On January 3, 2025, Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, engaged in transactions involving the company's common stock.
• Snyder acquired 7,611 shares of common stock through the vesting and settlement of restricted stock units (RSUs).
• Simultaneously, 4,289 shares were disposed of to cover tax withholding obligations at a price of $47.74 per share.
• Following these transactions, Snyder directly owns 15,002 shares of Halozyme Therapeutics common stock.
• He also directly owns 7,611 derivative securities in the form of restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing reflecting standard compensation practices. The tax withholding is a normal occurrence.

Positives

• The vesting of restricted stock units indicates a belief in the company's future performance by the executive.

Negatives

• The sale of shares to cover tax obligations, while common, could be perceived negatively if the amount is significant.

Risks

• There are no specific risks highlighted in this document.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates